STOCK TITAN

Nephros director Arthur H. Amron buys 5,000 and 2,500 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Nephros Inc. director Arthur H. Amron reported a direct purchase of 5,000 common shares at a weighted average price of $2.995 per share on November 16, 2026; a footnote says the shares were purchased in two transactions at $2.99 and $3.00. He also reported a direct purchase of 2,500 shares at $2.84 per share on November 17, 2026. Separately, 25,546 common shares were held indirectly by Amron Holdings LLC, over which Amron has voting and dispositive power. His reported direct option positions cover 7,323 and 7,050 underlying shares. No Rule 10b5-1 plan is reported.

Insider Amron Arthur H
Role Director
Bought 7,500 shs ($22K)
Increase in Position 4.6%
Type Security Shares Price Value
Purchase Common Stock 2,500 $2.84 $7K
Purchase Common Stock F2 5,000 $2.995 $15K
Holding Stock Option (Right to Buy) F3 -- -- --
Holding Stock Option (Right to Buy) F4 -- -- --
Holding Common Stock F1 -- -- --
Holdings After Transaction: Common Stock — 169,637 shares (Direct); Stock Option (Right to Buy) — 14,373 options (Direct); Common Stock — 25,546 shares (Indirect, By Amron Holdings LLC)
Holdings Before and After: Common Stock, 162,137 to 169,637 shares (Direct)
Footnotes (4)
  1. F1. Held by Amron Holdings LLC, over which the Reporting Person has voting and dispositive power as its controlling person.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were purchased in two transactions at prices of $2.99 and $3.00, inclusive. The reporting person undertakes to provide to Nephros, Inc., any security holder of Nephros, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  3. F3. Fully vested.
  4. F4. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.
Direct purchase 5,000 shares at $2.995 per share November 16, 2026; reported as a weighted average price
Direct purchase 2,500 shares at $2.84 per share November 17, 2026
Indirect common-stock holding 25,546 shares Held by Amron Holdings LLC; Amron has voting and dispositive power
Direct option position 7,323 underlying shares; $2.13 exercise price Expires May 14, 2034; fully vested
Direct option position 7,050 underlying shares; $1.47 exercise price Expires January 1, 2035; vests as to 2,350 shares on each of January 1, 2025, January 1, 2026, and January 1, 2027
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Fully vested financial
"Fully vested."
voting and dispositive power regulatory
"has voting and dispositive power as its controlling person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Arthur H. Amron buy in NEPH?

He reported a direct purchase of 5,000 shares on November 16 and 2,500 shares on November 17, 2026. No Rule 10b5-1 plan is reported.

What prices did Arthur H. Amron pay for NEPH shares?

For the November 16 purchase, 5,000 shares were reported at a weighted average price of $2.995 per share; a footnote says the purchases were at $2.99 and $3.00. The November 17 purchase was reported at $2.84 per share.

What option positions does Arthur H. Amron have in NEPH?

He has a fully vested option covering 7,323 underlying common shares at a $2.13 exercise price, expiring May 14, 2034. A second option covers 7,050 shares at $1.47, expires January 1, 2035, and vests as to 2,350 shares on each of January 1, 2025, January 1, 2026, and January 1, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Amron Arthur H

(Last)(First)(Middle)
C/O NEPHROS, INC., 380 LACKAWANNA PLACE

(Street)
SOUTH ORANGE NEW JERSEY 07079

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
NEPHROS INC [ NEPH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock25,546IBy Amron Holdings LLC(1)
Common Stock11/16/2026P5,000A$2.995(2)167,137D
Common Stock11/17/2026P2,500A$2.84169,637D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$2.13 (3)05/14/2034Common Stock7,3237,323D
Stock Option (Right to Buy)$1.47 (4)01/01/2035Common Stock7,0507,050D
Explanation of Responses:
1. Held by Amron Holdings LLC, over which the Reporting Person has voting and dispositive power as its controlling person.
2. The price reported in Column 4 is a weighted average price. These shares were purchased in two transactions at prices of $2.99 and $3.00, inclusive. The reporting person undertakes to provide to Nephros, Inc., any security holder of Nephros, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
3. Fully vested.
4. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.
/s/ Arthur H. Amron11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading